Investment Rating - The report maintains a BUY rating for Meidong Auto, indicating potential for over 15% return over the next 12 months [1][8]. Core Insights - Despite ongoing industry challenges, Meidong Auto has sustained healthy cash flow and a solid balance sheet, positioning it well for future growth [1]. - The new-car gross profit margin (GPM) is expected to recover in FY26, particularly as foreign luxury car manufacturers adjust their sales volume and pricing expectations [1]. - Meidong has diversified its business by starting an electric vehicle (EV) brand dealership, which is anticipated to enhance operational efficiency and competitiveness [1]. Financial Summary - Revenue is projected to decline from RMB 20,023 million in FY25A to RMB 18,292 million in FY26E, with a slight recovery to RMB 18,455 million in FY27E [2]. - Net profit is expected to turn positive in FY26E at RMB 146 million, and further increase to RMB 328 million in FY27E, reflecting a significant year-on-year growth of 124.4% [2][10]. - The gross profit margin is forecasted to improve from -3.8% in FY26E to -2.1% in FY27E, contributing to a net margin increase from 1.8% in FY27E [10][12]. Target Price and Valuation - The target price has been adjusted from HK$2.80 to HK$2.20, representing a 57.1% upside from the current price of HK$1.40 [3][8]. - The valuation is based on a revised FY27E P/E ratio of 8x [8]. Share Performance - The market capitalization of Meidong Auto is approximately HK$1,884.7 million, with a 52-week high of HK$2.34 and a low of HK$1.16 [3]. - Recent share performance shows a decline of 15.2% over the past month and a 30.3% decline over the past six months [5].

Macro Commentary - China's manufacturing PMI rebounded significantly in March, partly due to the later and longer Spring Festival holiday in 2026, although it remains in a contraction state based on the three-month moving average. Both supply and demand have improved significantly, with inventory cycles and import/export orders showing recovery [2] - The non-manufacturing PMI slightly increased, indicating a return to expansion in the service sector, while the construction sector remains in contraction. The price indices for both manufacturing and services suggest that upstream input inflation may lead to a positive PPI in the coming months [2] - The overall resilience of the RMB is maintained, fluctuating around 6.9 against the USD despite a strong dollar backdrop [4] Company Analysis Sunny Optical Technology (2382 HK) - The company is expected to achieve a revenue and net profit growth of 21% and 85% year-on-year in the second half of 2025, reaching RMB 23.6 billion and RMB 3 billion respectively. The net profit aligns with previous positive forecasts and exceeds market consensus by 44% due to a one-time investment gain from GoerTek [5] - Management guidance for 2026 indicates revenue and net profit growth of no less than 7% each, driven by a 5-10% increase in smartphone revenue and a 60% increase in IoT revenue, offsetting weakness in XR business [5] Yongda Automobile (3669 HK) - The company anticipates a significant impairment in 2025, with revenue expected to decline by 15% to RMB 27.5 billion in the second half of 2025, leading to a historical low overall gross margin of 7.0%. A total impairment of approximately RMB 4.9 billion is expected, resulting in a net loss of RMB 1.7 billion in the second half of 2025 [5] - Management plans to close 15-20 stores in 2026, with most related asset impairments already accounted for in 2025, suggesting no major impairments in 2026 [6] Sanofi Pharmaceutical (1530 HK) - The company is projected to achieve a revenue of RMB 17.7 billion in 2025, a 94.3% year-on-year increase, primarily due to a RMB 9.4 billion licensing income from Pfizer. However, product sales are expected to decline by 10.3% to RMB 8 billion due to national procurement policies [7] - The company is expected to maintain high levels of R&D investment to accelerate pipeline progress, with significant clinical advancements anticipated from the collaboration with Pfizer [8] Kanglong Chemical (300759 CH) - The company reported a 14.8% year-on-year revenue growth to RMB 14.1 billion in 2025, with adjusted net profit increasing by 13.0% to RMB 1.82 billion, both exceeding previous forecasts [10] - Management expects a revenue growth of 12-18% in 2026, with currency fluctuations negatively impacting growth guidance by 3 percentage points [11] Zhongji Xuchuang (300308 CH) - The company reported a strong FY25 performance with a revenue growth of 60% to RMB 38.2 billion and a net profit increase of 109% to RMB 10.8 billion, aligning with market expectations [14] - The gross margin improved significantly from 34.7% in FY24 to 42.6% in FY25, driven by strong shipments of high-speed optical modules and an increase in the proportion of silicon photonics products [14] OmniVision Technologies (603501 CH) - The company achieved a revenue growth of 12.1% to RMB 28.9 billion in FY25, with a net profit increase of 21.7% to RMB 4 billion, although slightly below market expectations [15] - The gross margin improved from 29.4% in FY24 to 30.6% in FY25, primarily due to the optimization of CIS product structure and increased contributions from automotive CIS revenue [15]

Investment Rating - The report maintains a "BUY" rating for Sunny Optical, with a new target price of HK$82.99, implying a 55.3% upside from the current price of HK$53.45 [3][16]. Core Insights - Sunny Optical's revenue and net profit for 2H25 grew by 21% and 85% year-over-year, respectively, largely in line with prior positive profit alerts and estimates, but significantly above consensus estimates due to a one-off investment gain [1][9]. - For 2026, management guided for revenue and net profit growth of not less than 7% year-over-year, driven by a 5-10% increase in smartphone revenue and a 60% increase in IoT revenue, despite challenges in the XR segment [1][9]. - The focus on high-end specifications and a strong IoT product pipeline are expected to be major growth drivers in 2026, even amid near-term headwinds in the smartphone and automotive industries [1][9]. Financial Summary - Revenue projections for FY25E are set at RMB43.23 billion, with a year-over-year growth of 12.9%, and for FY26E at RMB45.91 billion, with a growth of 6.2% [2][24]. - Net profit for FY25E is estimated at RMB4.64 billion, reflecting a 71.9% increase year-over-year, while FY26E net profit is projected at RMB4.15 billion, a decrease of 10.4% [2][24]. - The report indicates an adjusted forecast for FY26-27E, reflecting better-than-expected results and guidance for FY25 [1][12]. Segment Performance - The handset segment is expected to see revenue growth of 5-10% year-over-year, with improvements in gross profit margins [9][15]. - The vehicle segment is projected to grow by 15% year-over-year, driven by advancements in ADAS and other automotive technologies [9][15]. - The XR segment is anticipated to decline by 16% year-over-year due to client transitions, although growth in optical engines and AR systems is expected to commence in FY27 [9][15]. Valuation - The target price of HK$82.99 is derived from a sum-of-the-parts (SOTP) valuation, applying different P/E multiples to various business segments, reflecting Sunny's diversified growth profiles [16][18]. - The handset business is assigned a P/E of 20x, the vehicle segment 23x, the XR products 25x, and other products 15x, indicating a strategic approach to valuation based on market leadership and growth potential [17][18].

Investment Rating - The report maintains a "BUY" rating for Pharmaron Beijing, indicating a potential return of over 15% over the next 12 months [18]. Core Insights - Pharmaron reported a revenue growth of 14.8% YoY to RMB 14.10 billion and a non-IFRS adjusted net profit increase of 13.0% YoY to RMB 1.82 billion for 2025, both exceeding estimates [1][2]. - The company expects revenue growth of 12-18% YoY in 2026, factoring in a negative impact of 3 percentage points from foreign exchange [1]. - A significant CDMO deal with Eli Lilly is expected to enhance future growth, with Eli Lilly investing US$200 million to support Pharmaron's technical capabilities [9]. Financial Performance - For FY25, revenue was RMB 14,095 million, with a YoY growth of 14.8% and adjusted net profit of RMB 1,816 million, reflecting a 13.0% YoY increase [2]. - Revenue projections for FY26, FY27, and FY28 are RMB 16,410 million, RMB 19,019 million, and RMB 21,855 million, respectively, with YoY growth rates of 16.4%, 15.9%, and 14.9% [2]. - Adjusted net profit is expected to reach RMB 2,156 million, RMB 2,537 million, and RMB 2,955 million for FY26, FY27, and FY28, with corresponding YoY growth rates of 18.7%, 17.7%, and 16.5% [2]. Valuation - The target price for Pharmaron has been raised from RMB 38.08 to RMB 39.00, reflecting a 39.4% upside from the current price of RMB 27.98 [3]. - The DCF-based valuation incorporates a WACC of 9.32% and a terminal growth rate of 2.0% [9][12]. Market Position - Revenue from global Top 20 pharma clients surged by 29.4% YoY, significantly outpacing the company's overall growth, while revenue from European clients grew by 27.4% YoY [9]. - Newly signed orders increased by over 14% YoY, continuing a robust growth trend following a greater than 20% YoY increase in 2024 [9].

Investment Rating - The report maintains a BUY rating for Innolight, with a target price of RMB707, indicating a potential upside of 24.2% from the current price of RMB569.41 [3][4]. Core Insights - Innolight reported strong FY25 earnings, with revenue increasing by 60% YoY to RMB38.2 billion and net profit rising by 109% YoY to RMB10.8 billion, reflecting robust demand and effective execution [1][2]. - The gross profit margin (GPM) improved significantly to 42.6% from 34.7% in FY24, driven by high-speed optical module shipments and a higher silicon photonics (SiPh) mix [1][2]. - The company is positioned as a key beneficiary in the domestic AI sector, supported by enhanced supply-chain readiness and leadership in pluggable modules [1]. Financial Summary - Revenue projections for FY26E are set at RMB84.1 billion, with a YoY growth of 119.8%, and net profit is expected to reach RMB28.0 billion, reflecting a 159.7% increase [2][10]. - The gross margin is anticipated to further improve to 45.6% in FY26E and 48.5% by FY28E, indicating ongoing operational efficiency [2][19]. - The earnings per share (EPS) is projected to grow from RMB9.80 in FY25A to RMB25.24 in FY26E, with a P/E ratio decreasing from 58.1 in FY25A to 22.6 in FY26E [2][19]. Growth and Capacity - Capacity expanded by 34% YoY in FY25, with shipments growing by 45%, highlighting strong demand and effective ramp execution [9]. - Utilization rates improved from 74% in FY24 to 85% in FY25, with overseas sales constituting 92% of revenue [9]. - The company expects 800G to remain a primary shipment driver, while 1.6T technology is anticipated to significantly contribute to revenue and GPM growth [9]. Market Position and Future Outlook - Innolight's product roadmap is considered one of the strongest in the sector, with management focusing on 800G and 1.6T as core demand pillars for FY26 [9]. - The company is also preparing for future optical interconnect demand, with plans to introduce 3.2T pluggable modules by FY28E [9]. - The report indicates an optimistic earnings outlook, driven by sustained growth in 800G volumes and increased contributions from 1.6T technology [9].

Investment Rating - The report maintains a "BUY" rating for 3SBio, indicating a potential return of over 15% over the next 12 months [6][15]. Core Insights - 3SBio reported a revenue of RMB 17.7 billion in 2025, a significant increase of 94.3% year-over-year, primarily driven by RMB 9.4 billion in out-licensing income from Pfizer for product 707. However, product sales experienced a decline of 10.3% year-over-year to RMB 8.0 billion due to challenges from China's VBP and reimbursement controls [1][2]. - The company is expected to maintain high R&D investments to accelerate pipeline progress, with a focus on product 707, which is seen as the primary valuation anchor due to Pfizer's aggressive global development strategy [1][6]. - The report anticipates that while commercialized products, especially TPIAO, may face continued pressure in 2026, new product approvals and pipeline candidates could help offset declines in traditional product sales [6][8]. Financial Summary - Revenue projections for 2026 are revised down to RMB 9.17 billion, reflecting a 48.2% decline from 2025, with a net profit forecast of RMB 1.90 billion, down 77.6% year-over-year [2][7]. - The report highlights a significant increase in R&D and administrative expense ratios, which rose approximately 4 percentage points and 2 percentage points, respectively, due to accelerated clinical investments and one-off share-based compensation [1][6]. - The target price for 3SBio has been adjusted to HK$ 34.87 from a previous HK$ 37.43, representing a 54% upside from the current price of HK$ 22.64 [3][6]. Pipeline and Product Development - 3SBio has developed a broad pipeline of 27 candidates, with several already obtaining US FDA INDs, including SSS67 and SSS68, which target various medical conditions and demonstrate the company's global R&D strategy [6][8]. - Near-term catalysts include updated Phase 2 data for NSCLC and EC at ASCO 2026, which are expected to drive milestone payments and enhance earnings [6][8]. - Recent product approvals, such as NuPIAO and SSS20, along with NRDL inclusion for oral paclitaxel, are anticipated to generate revenue in 2026 and partially offset declines from traditional products [6][8].

Investment Rating - Maintain BUY rating for Yongda Automobiles, indicating potential for significant returns despite current challenges [1][8] Core Views - The report suggests that further deterioration in new-car gross profit margins (GPM) is limited due to luxury OEMs lowering manufacturer suggested retail prices (MSRPs) and exploring agency models [1] - The auto dealer industry is in a "survival of the fittest" phase, with established leaders like Yongda expected to be long-term survivors [1] - Yongda's expertise in new energy vehicle (NEV) dealership is viewed as a key competitive advantage as most brands will continue to rely on dealers [1] Financial Summary - Revenue projections show a decline from RMB 74,296 million in FY23A to RMB 54,600 million in FY25E, with a YoY growth of -14.6% in FY24A and -13.9% in FY25E [2][12] - Net profit is expected to drop significantly, from RMB 572.6 million in FY23A to a loss of RMB 5,071.5 million in FY25E, with a recovery projected in FY26E to RMB 38 million [2][12] - Earnings per share (EPS) is forecasted to decrease from RMB 0.29 in FY23A to a loss of RMB 2.72 in FY25E, with a slight recovery to RMB 0.02 in FY26E [2][12] Target Price and Valuation - The target price for Yongda has been revised down from HK$2.50 to HK$1.80, reflecting a 29.5% upside from the current price of HK$1.39 [3] - The valuation is based on a 10x FY27E P/E, indicating increased sensitivity to new-car GPM recovery [8] Earnings and Margin Projections - New-car GPM is projected to recover from 0.1% in FY25 to 0.3% in FY26E, driven by increased transaction prices and OEMs' MSRP cuts [8] - The report anticipates stable operating expenses despite potential revenue declines due to planned store closures [8] Share Performance - The stock has experienced a decline of 27.2% over the past six months, indicating market challenges [5]

Investment Rating - The report maintains a "Buy" rating for OmniVision with a target price adjusted to RMB 136, based on a forecasted P/E ratio of 33.0x for FY26, consistent with the company's historical average P/E ratio over the past two years [1][3]. Core Insights - OmniVision reported a revenue increase of 12.1% year-on-year to RMB 28.9 billion for FY25, which was below both the report's estimates and Bloomberg consensus by 5%. Net profit grew by 21.7% year-on-year to RMB 4.0 billion, also falling short of expectations by 2% and 9% respectively. The gross margin improved to 30.6% from 29.4% in FY24, primarily due to a richer CIS product mix and increased contributions from automotive CIS [1][2][3]. - The core CIS business continues to achieve structural mixed upgrades, with growth increasingly driven by high-value automotive, emerging/IoT, and medical applications rather than solely mobile devices. Core CIS revenue grew by 10.7% year-on-year, with automotive, emerging, and IoT/medical contributing 35%, 11%, and 5% respectively to departmental sales, up from 31%, 4%, and 3.5% in FY24 [2][3]. - The management anticipates a revenue range of RMB 6.2 billion to RMB 6.5 billion for Q1 FY26, indicating a year-on-year decline of 2.3% and a quarter-on-quarter decline of 11%. The expected gross margin is projected to be between 28.7% and 29.6%, impacted by rising component costs, particularly related to memory inflation [1][2]. Financial Summary - For FY25, OmniVision's revenue was RMB 28.9 billion, with a year-on-year growth of 12.1%. The projected revenues for FY26, FY27, and FY28 are RMB 34.1 billion, RMB 40.1 billion, and RMB 47.1 billion respectively, reflecting growth rates of 18.0%, 17.7%, and 17.6% [4][17]. - The net profit for FY25 was RMB 4.0 billion, with a year-on-year growth of 21.7%. The projected net profits for FY26, FY27, and FY28 are RMB 4.98 billion, RMB 6.75 billion, and RMB 8.86 billion respectively, indicating growth rates of 23.1%, 35.6%, and 31.3% [4][17]. - The gross margin is expected to improve from 30.6% in FY25 to 31.8% in FY26, and further to 34.6% by FY28 [4][17].

Company Insights - Jitu Express (1519 HK) is expected to achieve a 112% year-on-year increase in adjusted net profit to USD 425 million in 2025, exceeding previous estimates by 22% and 16% respectively, with a strong performance in the second half of 2025 [2] - Zoomlion (1157 HK) anticipates a 36% year-on-year increase in net profit to RMB 4.8 billion in 2025, with a significant 60% increase in overseas revenue in Q4 2025 [5] - Zhengli New Energy (3677 HK) expects a 50% year-on-year increase in revenue to RMB 4.9 billion in the second half of 2025, with a gross margin reaching a historical high of 18.7% [5][6] - Angelalign (6699 HK) reported a 37.8% year-on-year increase in revenue to USD 370 million for the 2025 fiscal year, driven by strong overseas market expansion [8][9] - BYD Electronics (285 HK) anticipates stable revenue growth in 2026, primarily driven by high-end smartphone components and AI server products [11] - China Life (2628 HK) reported a 44.1% year-on-year increase in net profit to RMB 154 billion for 2025, with a significant increase in new business value [21][22] Industry Trends - The Southeast Asian market is showing strong growth potential, with Jitu Express expanding its market share significantly [2][5] - The electric vehicle battery market is expected to see increased demand, with Zhengli New Energy projecting a rise in battery shipment volumes [6][7] - The Chinese insurance market is experiencing a shift towards improved underwriting profitability, as evidenced by China Life's performance [21][22] - The smart cockpit industry is projected to grow at a CAGR of 18.4% from 2024 to 2029, with companies like Botai leading the charge [15][16] - The biopharmaceutical sector is witnessing a surge in innovative drug approvals, with China Biopharmaceuticals expanding its product pipeline significantly [17][18]

Investment Rating - The report maintains a "Buy" rating for InnoScience with a target price adjusted to HKD 75, based on a projected P/E ratio of 35 times for 2030 [1][3]. Core Insights - InnoScience reported a revenue growth of 46.4% year-on-year to RMB 1.2 billion for fiscal year 25, which was below the analyst's estimate of 9% and the Bloomberg consensus of 11% [1]. - The gross margin improved from -19.5% in fiscal year 24 to 7.3% in fiscal year 25, although it was still below the analyst's estimate by 3.3 percentage points [1]. - The company achieved a positive adjusted EBITDA for the first time, indicating a significant operational turning point [1]. - Key milestones for fiscal year 25 included collaborations with leading AI clients like Nvidia and Google, entry into humanoid robotics, and progress in automotive applications [1][2]. Revenue and Market Segmentation - The consumer market accounted for approximately 50% of total sales in fiscal year 25, down from 60% in fiscal year 24, while the industrial market rose to 43% from about 30% [2]. - Data center revenue grew by 50.2% year-on-year to RMB 63 million, representing 5.2% of total sales, and automotive business revenue more than doubled to RMB 58 million, accounting for 4.8% of total sales [2]. - The product mix is shifting, with wafer sales declining by 10% to represent 21% of total sales, while revenue from chips + ICs and modules grew by 41% and 143%, contributing 42% and 37% respectively [2]. Capacity Expansion and Strategic Positioning - The report emphasizes that capacity scale is crucial for the company's technological leadership and long-term profitability [3]. - InnoScience plans to achieve a production capacity of 80k wafers per minute by 2028, which is expected to enhance profitability through better utilization and reduced unit costs [3]. - The company is well-positioned to expand its adoption in higher-value applications due to limited competition in the pure-play GaN sector [3]. Financial Projections - Revenue projections for fiscal years 26 to 28 are RMB 2.08 billion, RMB 3.05 billion, and RMB 4.45 billion, respectively, with year-on-year growth rates of 71.5%, 46.6%, and 46.0% [4]. - Gross profit margins are expected to improve significantly, reaching 22.5% in fiscal year 26, 33.4% in fiscal year 27, and 40.5% in fiscal year 28 [4]. - The company is projected to reach a net profit of RMB 590 million by fiscal year 28, with a corresponding EPS of RMB 0.67 [4].